Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOA | P21397 | 6/20 | 0.58 |
| ▸ | MAOB | P27338 | 5/20 | 0.58 |
| ▸ | SLC18A3 | Q16572 | 3/20 | 0.57 |
| ▸ | DRD2 | P14416 | 1/20 | 0.57 |
| ▸ | SIGMAR1 | Q99720 | 4/20 | 0.53 |
| ▸ | MEN1 | O00255 | 2/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.53 |
| ▸ | CARM1 | Q86X55 | 1/20 | 0.53 |
| ▸ | PRMT6 | Q96LA8 | 1/20 | 0.53 |
| ▸ | TP53 | P04637 | 1/20 | 0.51 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.51 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.51 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.51 |
| ▸ | TSHR | P16473 | 1/20 | 0.51 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.51 |
| ▸ | BCHE | P06276 | 1/20 | 0.50 |
| ▸ | KCNA3 | P22001 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL81671 | 0.83 | MAOB (0.60) | MAOAMAOBSLC18A3DRD2 | |
| SCHEMBL9476556 | 0.83 | SLC18A3 (0.63) | SLC18A3DRD2SIGMAR1MEN1KMT2A | |
| SCHEMBL14328412 | 0.82 | SLC18A3 (0.57) | SLC18A3DRD2SIGMAR1MEN1KMT2A | |
| SCHEMBL10696270 | 0.82 | SLC18A3 (0.57) | SLC18A3DRD2SIGMAR1MEN1KMT2A | |
| SCHEMBL16364107 | 0.81 | DRD2 (0.67) | MAOAMAOBDRD2BCHE | |
| SCHEMBL16829624 | 0.81 | DRD2 (0.63) | MAOBDRD2SIGMAR1 | |
| SCHEMBL22485567 | 0.79 | DRD2 (0.58) | SLC18A3DRD2SIGMAR1MEN1KMT2A | |
| SCHEMBL7403433 | 0.77 | MAOB (0.49) | MAOAMAOBBCHE | |
| SCHEMBL9369758 | 0.76 | SLC18A3 (0.69) | SLC18A3DRD2SIGMAR1MEN1KMT2A | |
| SCHEMBL18026661 | 0.76 | MAOA (0.72) | MAOAMAOBSIGMAR1CARM1PRMT6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0537008-B1 | Use of biphosphonates for the manufacture of a medicament for blocking neoplastic transformation of cells induced by ras oncogenes | SQUIBB & SONS INC (US) | 1995-10-25 | — | — | EP | claimed |
| US-20260125349-A1 | PROCESS FOR THE FLUORINATION AND/OR CYCLIZATION OF AN AMINO ALKENE OR ALKYNE IN A CONTINUOUS STREAM AND FACILITY FOR PERFORMING THE PROCESS | UNIV POITIERS (FR) | 2026-05-07 | — | — | US | disclosed |
| EP-4598903-A1 | PROCESS FOR THE FLUORINATION AND/OR CYCLIZATION OF AN AMINO ALKENE OR ALKYNE IN A CONTINUOUS STREAM AND FACILITY FOR PERFORMING THE PROCESS | Université de Poitiers (FR) | 2025-08-13 | — | — | EP | disclosed |
| CN-120035579-A | Process for fluorinating and/or cyclizing an amino alkene or alkyne in a continuous flow and apparatus for carrying out the process | 普瓦捷大学 | 2025-05-23 | — | — | CN | disclosed |
| WO-2024074501-A1 | PROCESS FOR THE FLUORINATION AND/OR CYCLIZATION OF AN AMINO ALKENE OR ALKYNE IN A CONTINUOUS STREAM AND FACILITY FOR PERFORMING THE PROCESS | UNIVERSITE DE POITIERS (FR) | 2024-04-11 | — | — | WO | disclosed |
| US-10301267-B2 | Compounds | ASTRAZENECA AB (SE) | 2019-05-28 | — | — | US | disclosed |
| US-9902711-B2 | Piperidine compounds having multimodal activity against pain | LABORATORIOS DEL DR. ESTEVE S.A. (ES) | 2018-02-27 | — | — | US | disclosed |
| US-20170260143-A1 | NOVEL COMPOUNDS | ASTRAZENECA AB (SE) | 2017-09-14 | — | — | US | disclosed |
| US-9688640-B2 | Methods of treating cancer with a pyrazole derivative | ASTRAZENECA AB (SE) | 2017-06-27 | — | — | US | disclosed |
| US-20170001979-A1 | Piperidine compounds having multimodal activity against pain | ESTEVE PHARMACEUTICALS, S.A. (ES) | 2017-01-05 | — | — | US | disclosed |
| EP-2246329-A1 | 4(1H)-pyridinone derivatives and their use as antimalaria agents | Glaxo Group Limited (GB) | 2010-11-03 | — | — | EP | disclosed |
| WO-2010081904-A1 | 4 ( 1H) -PYRIDINONE DERIVATIVES AND THEIR USE AS ANTIMALARIA AGENTS | GLAXO GROUP LIMITED (GB) | 2010-07-22 | — | — | WO | disclosed |
| EP-1423363-B1 | ORAL ANTIDIABETIC AGENTS | WARNER LAMBERT CO (US) | 2006-04-19 | — | — | EP | disclosed |
| EP-1577305-A1 | Oral antidiabetic agents | WARNER-LAMBERT COMPANY LLC (US) | 2005-09-21 | — | — | EP | disclosed |
| CN-1558897-A | oral antidiabetic agent | ����-�����ع�˾ | 2004-12-29 | — | — | CN | disclosed |
| EP-1423363-A1 | ORAL ANTIDIABETIC AGENTS | Warner-Lambert Company LLC (US) | 2004-06-02 | — | — | EP | disclosed |
| US-20030171377-A1 | Antidiabetic agents | BIGGE CHRISTOPHER FRANKLIN (US) | 2003-09-11 | — | — | US | disclosed |
| WO-2003018553-A1 | ORAL ANTIDIABETIC AGENTS | WARNER-LAMBERT COMPANY LLC (US) | 2003-03-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030171377-A1 | Antidiabetic agents | SLC5A1, SLC5A2, GLP1R | MAOA 1046/4885MAOB 316/4885SLC18A3 3547/4885 |
| US-10301267-B2 | Compounds | SLC10A1, CYP11B1, ABCB11 | MAOA 1555/4885MAOB 1283/4885SLC18A3 3899/4885 |
| US-20260125349-A1 | PROCESS FOR THE FLUORINATION AND/OR CYCLIZATION OF AN AMINO ALKENE OR ALKYNE IN A CONTINUOUS STREAM AND FACILITY FOR PERFORMING THE PROCESS | FIBP, FGB, SUB1 | MAOA 876/4885MAOB 343/4885SLC18A3 3536/4885 |
| US-20170260143-A1 | NOVEL COMPOUNDS | SLC10A1, ABCB11, CYP11B1 | MAOA 3474/4885MAOB 2776/4885SLC18A3 3829/4885 |
| US-20170001979-A1 | Piperidine compounds having multimodal activity against pain | OPRD1, OPRM1, OPRL1 | MAOA 947/4885MAOB 1266/4885SLC18A3 934/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.